Capricor Therapeutics
CAPR
25 hedge funds and large institutions have $6.8M invested in Capricor Therapeutics in 2021 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 8 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
1.21% less ownership
Funds ownership: 10.82% → 9.61% (-1.2%)
17% less funds holding
Funds holding: 30 → 25 (-5)
32% less capital invested
Capital invested by funds: $10M → $6.8M (-$3.23M)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
71% less call options, than puts
Call options by funds: $311K | Put options by funds: $1.07M
Top Buyers
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$237K |
| 2 |
JF
Jump Financial
Chicago,
Illinois
|
+$79.9K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$64.6K |
| 4 |
Goldman Sachs
New York
|
+$29K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$13.1K |
Top Sellers
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$388K |
| 2 |
VF
Virtu Financial
New York
|
-$222K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
-$215K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$111K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$83.3K |
CAPR Hedge Fund Activity: Q4 2021 in Review
25 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q4 2021, worth a combined $6.8M — down 32% from $10M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of CAPR and 3 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 7 added.
The largest buyer was Dimensional Fund Advisors, adding an estimated $237K. The largest seller was GSA Capital Partners, exiting entirely with an estimated $388K sold.
- 25 institutional investors held Capricor Therapeutics (CAPR) as of Q4 2021, down from 30 in Q3 2021.
- Funds reported $6.8M of Capricor Therapeutics stock for Q4 2021, down 32% quarter-over-quarter.
- 3 funds opened new Capricor Therapeutics positions in Q4 2021 and 8 closed out, a net change of -5 holders.
- The largest Capricor Therapeutics buyer in Q4 2021 was Dimensional Fund Advisors, an estimated $237K added.
- The largest Capricor Therapeutics seller in Q4 2021 was GSA Capital Partners, an estimated $388K sold.
Based on aggregated 13F filings for Q4 2021.